Innate Pharma S.A. (EPA:IPH)

Market Cap	110.34M -23.5%
Revenue (ttm)	9.01M -55.2%
Net Income	-49.18M
EPS	-0.55
Shares Out	93.83M
PE Ratio	n/a
Forward PE	1.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	271,922
Average Volume	413,610
Open	1.170
Previous Close	1.176
Day's Range	1.154 - 1.206
52-Week Range	1.030 - 2.100
Beta	0.74
RSI	44.52
Earnings Date	Mar 26, 2026

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 174
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPH

Financial Performance

In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.